B-057 From Plasma to Whole Blood: Validation of GFAP and NFL as Accessible Biomarkers in Stroke
Abstract
Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) are critical blood-based biomarkers for the diagnosis and monitoring of a wide range of central nervous system (CNS) injuries. Current plasma-based assays require centrifugation, which prolongs turnaround time (TAT) and limits utility in emergency settings. Specifically in acute stroke management, rapid differentiation between hemorrhagic and ischemic subtypes is essential, and GFAP/NfL have shown utility in this application. This study aimed to develop and validate a rapid, automated chemiluminescence immunoassay for the direct quantification of GFAP and NfL in whole blood. We used a dual-antibody sandwich chemiluminescence immunoassay to measure GFAP and NfL in blood samples. The assay was optimized for whole blood through reagent formulation adjustments, including the addition of surfactants (0.3% Tween 20 for GFAP, 0.5% Tween 20 for NfL), and implementation of a hematocrit (HCT) correction algorithm. Performance was evaluated in terms of precision, linearity, limit of quantification, and interference. A total of 115 paired whole blood and plasma samples from 78 acute stroke patients were analyzed to assess consistency and diagnostic accuracy. The HCT correction algorithm effectively minimized measurement bias across a wide HCT range (35%–55%), improving whole blood accuracy. Precision for GFAP and NfL in whole blood and plasma showed coefficients of variation (CV) below 5% across a broad concentration range. Excellent correlations were observed between whole blood (HCT-corrected) and plasma measurements for both GFAP (R² = 0.990) and NfL (R² = 0.955). Bland-Altman analysis indicated acceptable agreement, with mean biases of -11.96% for GFAP and 18.37% for NfL. The diagnostic accuracy for distinguishing hemorrhagic from ischemic stroke was comparable between whole blood and plasma (AUC 0.86 vs. 0.84, p=0.58). The novel whole blood assay provides a rapid, precise, and reliable method for quantifying GFAP and NfL without centrifugation, delivering results within 30 minutes. Its strong concordance with plasma measurements and broad analytical range support its potential to expedite stroke diagnosis and triage in acute care settings.